Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is making waves in the fight against B-cell malignancies
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated